Promius launches atopic dermatitis product in US
This article was originally published in Scrip
Executive Summary
Promius Pharma, a wholly owned US subsidiary ofDr Reddy's Laboratories, has launched its first product, a novel treatment for atopic dermatitis, on the US market. The prescription product, EpiCeram skin barrier emulsion, is based on scientific advances in the understanding of the skin barrier and its role in the pathogenesis of atopic dermatitis. It provides an optimal 3:1:1 ratio of ceramides, free fatty acids and cholesterol to help repair the damaged skin barrier and relieve the signs and symptoms of atopic dermatitis, the company says. The US market for atopic dermatitis is estimated at $400 million and the disease affects more than 15 million patients in the US. Promius, which expects to initially focus on the branded dermatology market, plans to launch three in-licensed and co-developed products in 2008-09. The company's current portfolio includes topical products for psoriasis, atopic dermatitis and seborrheic dermatitis.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet